Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathy

Journal of Heart and Lung Transplantation

Volumn 34, Issue 8, 2015, Pages 1050-1057

  Coutance, Guillaume ^a   Ouldamar, Salima ^a   Rouvier, Philippe ^b   Saheb, Samir ^c   Suberbielle, Caroline ^d   Bréchot, Nicolas ^b   Hariri, Sarah ^c   Lebreton, Guillaume ^a   Leprince, Pascal ^a   Varnous, Shaida ^a  

^a Cardiology Department   (France)

^b Department of Pathology ^*  (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

antibody mediated rejection; cardiac allograft vasculopathy; donor specific anti HLA antibodies; heart transplantation; survival

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; YOUNG ADULT; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; RETROSPECTIVE STUDY; TIME FACTOR;

ADULT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84938963056     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.03.002     Document Type: Article

References (20)

1. J.J. McMurray, S. Adamopoulos, S.D. Anker, and et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
2. K.K. Sureshkumar, S.M. Hussain, R.J. Marcus, and et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation Clin Nephrol 77 2012 246 253
3. J. Kobashigawa, M.G. Crespo-Leiro, S.M. Ensminger, and et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation J Heart Lung Transplant 30 2011 252 269
4. A.M. Hodges, H. Lyster, A. McDermott, and et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody Transplantation 93 2012 650 656
5. J.D. Smith, N.R. Banner, I.M. Hamour, and et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival Am J Transplant 11 2011 312 319
6. C. Dörje, K. Midtvedt, H. Holdaas, and et al. Early versus late acute antibody-mediated rejection in renal transplant recipients Transplantation 96 2013 79 84
7. A.G. Kfoury, G.L. Snow, D. Budge, and et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation J Heart Lung Transplant 31 2012 46 51
8. S. Stewart, G.L. Winters, M.C. Fishbein, and et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection J Heart Lung Transplant 24 2005 1710 1720
9. M.R. Mehra, M.G. Crespo-Leiro, A. Dipchand, and et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy - 2010 J Heart Lung Transplant 29 2010 717 727
10. M.R. Costanzo, A. Dipchand, R. Starling, and et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients J Heart Lung Transplant 29 2010 914 956
11. S. Chih, K.J. Tinckam, and H.J. Ross A survey of current practice for antibody-mediated rejection in heart transplantation Am J Transplant 13 2013 1069 1074
12. J. Gubensek, J. Buturovic-Ponikvar, A. Kandus, and et al. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study Transplant Proc 45 2013 1524 1527
13. J.A. Kobashigawa, L.W. Miller, S.D. Russell, and et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report Am J Transplant 6 2006 1377 1386
14. P.M. Eckman, M. Thorsgard, D. Maurer, Y. Kim, R.R. Alloway, and E.S. Woodle Bortezomib for refractory antibody-mediated cardiac allograft rejection Clin Transpl 2009 475 478
15. A. Idica, H. Kaneku, M.J. Everly, and et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib Clin Transpl 2008 229 239
16. J.K. Kirklin, R.N. Brown, S.T. Huang, and et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis J Heart Lung Transplant 25 2006 283 288
17. A.G. Kfoury, M.E.H. Hammond, G.L. Snow, and et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection J Heart Lung Transplant 28 2009 781 784
18. G.W. Wu, J.A. Kobashigawa, M.C. Fishbein, and et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes J Heart Lung Transplant 28 2009 417 422
19. A. Herskowitz, L.M. Soule, K. Ueda, and et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients J Heart Transplant 6 1987 127 136
20. E. Berglin, C. Kjellström, V. Mantovani, G. Stelin, C. Svalander, and L. Wiklund Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases Transpl Int 8 1995 382 387